{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:45:21Z","timestamp":1793882721323,"version":"4.7.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec id=\"ab-hoi240003-4\"><jats:title>Importance<\/jats:title><jats:p>Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking in patients with transthyretin (ATTR) amyloidosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240003-5\"><jats:title>Objective<\/jats:title><jats:p>To use CPET to characterize the spectrum of functional phenotypes in patients with ATTR amyloidosis and assess their association with the cardiac amyloid burden as well as the association between CPET parameters and prognosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240003-6\"><jats:title>Design, Setting and Participants<\/jats:title><jats:p>This single-center study evaluated patients diagnosed with ATTR amyloidosis from May 2019 to September 2022 who underwent CPET at the National Amyloidosis Centre. Of 1045 patients approached, 506 were included and completed the study. Patients were excluded if they had an absolute contraindication to CPET or declined participation. The mean (SD) follow-up period was 22.4 (11.6) months.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240003-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Comparison of CPET parameters across disease phenotypes (ATTR with cardiomyopathy [ATTR-CM], polyneuropathy, or both [ATTR-mixed]), differences in CPET parameters based on degree of amyloid infiltration (as measured by cardiovascular magnetic resonance [CMR] with extracellular volume mapping), and association between CPET parameters and prognosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240003-8\"><jats:title>Results<\/jats:title><jats:p>Among the 506 patients with ATTR amyloidosis included in this study, the mean (SD) age was 73.5 (10.2) years, and 457 participants (90.3%) were male. Impairment in functional capacity was highly prevalent. Functional impairment in ATTR-CM and ATTR-mixed phenotypes (peak mean [SD] oxygen consumption [VO<jats:sub>2<\/jats:sub>], 14.5 [4.3] mL\/kg\/min and 15.7 [6.2] mL\/kg\/min, respectively) was observed alongside impairment in the oxygen pulse, with ventilatory efficiency highest in ATTR-CM (mean [SD] ventilatory efficiency\/volume of carbon dioxide expired slope, 38.1 [8.6]). Chronotropic incompetence and exercise oscillatory ventilation (EOV) were highly prevalent across all phenotypes, with both the prevalence and severity being higher than in heart failure from different etiologies. Worsening of amyloid burden on CMR was associated with decline in multiple CPET parameters, although chronotropic response and EOV remained abnormal irrespective of amyloid burden. On multivariable Cox regression analysis, peak VO<jats:sub>2<\/jats:sub> and peak systolic blood pressure (SBP) were independently associated with prognosis (peak VO<jats:sub>2<\/jats:sub>: hazard ratio, 0.89 [95% CI, 0.81-0.99; <jats:italic>P<\/jats:italic>\u2009=\u2009.03]; peak SBP: hazard ratio, 0.98 [95% CI, 0.97-0.99; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240003-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, ATTR amyloidosis was characterized by distinct patterns of functional impairment between all disease phenotypes. A high prevalence of chronotropic incompetence, EOV, and ventilatory inefficiency were characteristic of this population. CPET parameters were associated with amyloid burden by CMR and with peak VO<jats:sub>2<\/jats:sub>, and SBP, which have been shown to be independent predictors of mortality. These findings suggest that CPET may be useful in characterizing distinct patterns of functional impairment across the spectrum of amyloid infiltration and predicting outcomes, and potentially offers a more comprehensive method of evaluating functional capacity for future prospective studies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.0022","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T16:01:14Z","timestamp":1709740874000},"page":"367","source":"Crossref","is-referenced-by-count":30,"title":["Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis"],"prefix":"10.1001","volume":"9","author":[{"given":"Rishi K.","family":"Patel","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandera","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation and Heart Failure Unit, Cardiology University Department, Scientific Institute for Research, Hospitalization and Healthcare MultiMedica, Sesto San Giovanni, Milan, Italy"},{"name":"Department of Biomedical Sciences for Health, University of Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Venneri","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"},{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Italy, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuf","family":"Razvi","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ioannou","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Chacko","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Naharro","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad U.","family":"Rauf","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Knight","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brown","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Petrie","sequence":"additional","affiliation":[{"name":"Eastman Dental Institute, University College London, University Street, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lachmann","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Muthurangu","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guazzi","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation and Heart Failure Unit, Cardiology University Department, Scientific Institute for Research, Hospitalization and Healthcare MultiMedica, Sesto San Giovanni, Milan, Italy"},{"name":"Department of Biomedical Sciences for Health, University of Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"hoi240003r1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10038","key":"hoi240003r2","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis.","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"hoi240003r3","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis.","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"1","key":"hoi240003r6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12931-021-01895-6","article-title":"Practical guide to cardiopulmonary exercise testing in adults.","volume":"23","author":"Glaab","year":"2022","journal-title":"Respir Res"},{"issue":"3","key":"hoi240003r7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1161\/01.CIR.83.3.778","article-title":"Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure.","volume":"83","author":"Mancini","year":"1991","journal-title":"Circulation"},{"issue":"7","key":"hoi240003r8","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0735-1097(97)00078-8","article-title":"Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure.","volume":"29","author":"Chua","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi240003r9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ahj.2003.07.014","article-title":"Peak VO2 and VE\/VCO2 slope in patients with heart failure: a prognostic comparison.","volume":"147","author":"Arena","year":"2004","journal-title":"Am Heart J"},{"issue":"24","key":"hoi240003r10","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1161\/01.CIR.101.24.2803","article-title":"Impairment of ventilatory efficiency in heart failure: prognostic impact.","volume":"101","author":"Kleber","year":"2000","journal-title":"Circulation"},{"issue":"3","key":"hoi240003r11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13506129.2018.1496077","article-title":"Peak V\u2019O2 is an independent predictor of survival in patients with cardiac amyloidosis.","volume":"25","author":"Hein","year":"2018","journal-title":"Amyloid"},{"issue":"2","key":"hoi240003r12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ejhf.v23.2","article-title":"Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.","volume":"23","author":"Nicol","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"hoi240003r13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.clml.2021.03.015","article-title":"Cardiopulmonary exercise testing in patients with cardiac amyloidosis.","volume":"21","author":"Bhutani","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"hoi240003r14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.amjcard.2019.03.035","article-title":"Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis.","volume":"124","author":"Yunis","year":"2019","journal-title":"Am J Cardiol"},{"issue":"3","key":"hoi240003r15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/13506129.2020.1722098","article-title":"Restrictive cardiac phenotype as primary cause of impaired aerobic capacity in Afro-Caribbean patients with val122ile variant transthyretin amyloid cardiomyopathy.","volume":"27","author":"Monfort","year":"2020","journal-title":"Amyloid"},{"issue":"3","key":"hoi240003r16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11739-020-02474-1","article-title":"Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients.","volume":"16","author":"Bartolini","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"11","key":"hoi240003r17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.cardfail.2021.06.022","article-title":"Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis.","volume":"27","author":"Dalia","year":"2021","journal-title":"J Card Fail"},{"key":"hoi240003r18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.898033","article-title":"Diagnostic and prognostic values of cardiopulmonary exercise testing in cardiac amyloidosis.","volume":"9","author":"Banydeen","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"hoi240003r19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008381","article-title":"Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy.","volume":"15","author":"Badr Eslam","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"24","key":"hoi240003r20","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"hoi240003r21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.","volume":"93","author":"Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"30","key":"hoi240003r22","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi240003r23","first-page":"296","article-title":"Mitral regurgitation in heart failure: insights from CPET combined with exercise echocardiography.","volume":"18","author":"Bandera","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"hoi240003r24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00289-2020","article-title":"Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry.","volume":"57","author":"Hall","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"hoi240003r25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests.","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"issue":"13","key":"hoi240003r26","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary exercise testing: what is its value?","volume":"70","author":"Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi240003r27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00149831-200308000-00008","article-title":"A critical appraisal of the prognostic value of the VE\/VCO2 slope in chronic heart failure.","volume":"10","author":"Tabet","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"2","key":"hoi240003r28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/CIR.0b013e3181e52e69","article-title":"Clinician\u2019s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association.","volume":"122","author":"Balady","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"hoi240003r29","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/CIRCULATIONAHA.110.940577","article-title":"Chronotropic incompetence: causes, consequences, and management.","volume":"123","author":"Brubaker","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"hoi240003r30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"hoi240003r31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1532-429X-16-2","article-title":"T1-mapping in the heart: accuracy and precision.","volume":"16","author":"Kellman","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"hoi240003r32","first-page":"467","article-title":"Cardiopulmonary exercise test: background, applicability and interpretation.","volume":"107","author":"Herdy","year":"2016","journal-title":"Arq Bras Cardiol"},{"issue":"14","key":"hoi240003r33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"hoi240003r34","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jcmg.2016.08.003","article-title":"Cardiac dysautonomia and survival in hereditary transthyretin amyloidosis.","volume":"9","author":"Goldstein","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"hoi240003r35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0167-5273(95)02316-O","article-title":"Chronotropic incompetence in chronic heart failure.","volume":"49","author":"Zweerink","year":"1995","journal-title":"Int J Cardiol"},{"issue":"3","key":"hoi240003r36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006331","article-title":"Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction.","volume":"13","author":"Sarma","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"12","key":"hoi240003r37","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jcmg.2016.07.008","article-title":"Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation.","volume":"9","author":"Algalarrondo","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"hoi240003r38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006000","article-title":"Prognostic value of cardiopulmonary exercise testing in heart failure with reduced, midrange, and preserved ejection fraction.","volume":"6","author":"Nadruz","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"hoi240003r39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.HCR.0000320071.89093.d6","article-title":"The ventilatory classification system effectively predicts hospitalization in patients with heart failure.","volume":"28","author":"Arena","year":"2008","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"2","key":"hoi240003r40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/euhj.1999.1863","article-title":"Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE\/VCO(2)slope and peak VO(2).","volume":"21","author":"Francis","year":"2000","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi240003r41","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00313-2019","article-title":"Amyloidosis of the respiratory system: 16 patients with amyloidosis initially diagnosed ante mortem by pulmonologists.","volume":"6","author":"Yamada","year":"2020","journal-title":"ERJ Open Res"},{"issue":"2","key":"hoi240003r42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02313-2016","article-title":"Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases.","volume":"49","author":"Ussavarungsi","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"hoi240003r43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/heart.88.6.615","article-title":"Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?","volume":"88","author":"Bernardi","year":"2002","journal-title":"Heart"},{"issue":"3","key":"hoi240003r44","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1378\/chest.124.3.1090","article-title":"Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role.","volume":"124","author":"Guazzi","year":"2003","journal-title":"Chest"},{"issue":"3","key":"hoi240003r45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4330\/wjc.v8.i3.258","article-title":"Exercise oscillatory ventilation: Mechanisms and prognostic significance.","volume":"8","author":"Dhakal","year":"2016","journal-title":"World J Cardiol"},{"issue":"3","key":"hoi240003r46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0735-1097(97)00533-0","article-title":"Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation.","volume":"31","author":"Osada","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"hoi240003r4","unstructured":"Alnylam. Alnylam reports positive topline results from APOLLO-B phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy. Accessed August 8, 2022. https:\/\/investors.alnylam.com\/press-release?id=26851"},{"key":"hoi240003r5","unstructured":"ClinicalTrials.gov. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial). Updated July 10, 2023. Accessed June 17, 2023. https:\/\/clinicaltrials.gov\/study\/NCT03860935"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2815660\/jamacardiology_patel_2024_oi_240003_1711658458.54609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:01:29Z","timestamp":1712761289000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2815660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.0022","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}